Filter posts

Peptimmune Collaborates with Walter Reed on Dengue Virus Vaccine

Peptimmune, Inc. has formed a collaboration with the Walter Reed Army Institute of Research and …

Patient groups eager to speed cures

The 8th Annual BIO Investor Forum is attracting patient advocacy and venture philanthropy groups from …

Plexxikon Announces PLX4032 Phase I Clinical Trial Results

Plexxikon Inc. reports positive clinical data from a Phase 1 extension study of PLX4032 (RG7204) …

Peptimmune Collaborates with Walter Reed on Dengue Virus Vaccine

Peptimmune, Inc. has formed a collaboration with the Walter Reed Army Institute of Research and …

Idera Pharmaceuticals Phase 2 Results for Renal Cell Carcinoma Therapy

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced final data results from a clinical trial evaluating IMO-2055, …

Cleveland BioLabs Receives Additional Funding for Radiation Project

Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced an additional $2.3 million in funding for a …

Dendreon’s PROVENGE making regulatory and commercialization progress

Dendreon Corporation (Nasdaq: DNDN) today reported regulatory and commercialization progress for PROVENGE® (sipuleucel-T), the company’s …

Inovio CEO Speaks at MIT Conference

Dr. J. Joseph Kim, CEO of Inovio Biomedical Corporation (NYSE Amex: INO), presented keynote remarks …

Xoma to develop antibody for H1N1 and H5N1

XOMA Ltd. (Nasdaq:XOMA) is developing an antibody that has been shown by Dana-Farber Cancer Institute …

The latest from GlobeImmune

Interview with Timothy C. Rodell, M.D., GlobeImmune CEO & President: Can you describe the top …